Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells

Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells

A vaccine to generate durable HIV broadly neutralizing antibodies (bnAb) from engineered B cells holds promise as an HIV functional cure. Here, the authors show that CRISPR/Cas-modified B cells expressing bnAbs as functional antigen receptors can be immunized to generate long-lived, germinal centre...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Deli Huang, Jenny Tuyet Tran, Alex Olson, Thomas Vollbrecht, Mary Tenuta, Mariia V. Guryleva, Roberta P. Fuller, Torben Schiffner, Justin R. Abadejos, Lauren Couvrette, Tanya R. Blane, Karen Saye, Wenjuan Li, Elise Landais, Alicia Gonzalez-Martin, William Schief, Ben Murrell, Dennis R. Burton, David Nemazee, James E. Voss
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/8f0e41a577a24e6390766e0efaf6153c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:A vaccine to generate durable HIV broadly neutralizing antibodies (bnAb) from engineered B cells holds promise as an HIV functional cure. Here, the authors show that CRISPR/Cas-modified B cells expressing bnAbs as functional antigen receptors can be immunized to generate long-lived, germinal centre matured bnAb memory and plasma cells in mice.

Ejemplares similares